is combining CBT with sertraline more effective than either alone for childhood anxiety?

Category: Anxiety

📊 14 findings in 1 studies
Intervention Condition Outcome / Effect Source
📊 sertraline up to
vs Pill placebo with identical me 		youth anxiety disorders (separation
Adolescents 		Combination treatment (CBT + sertraline) was superior to placebo at week 12 on parent-reported youth
b= -15.7, t= -6.4 (MASC-P); b= -9.8, t= 		↑ PMC6425733
12 weeks
📊 Sertraline monotherapy in youth ages 7-1
vs Pill placebo with identical me 		youth anxiety disorders (separation
Children 		Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms
b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= 		↑ PMC6425733
12 weeks
📊 Sertraline
vs Pill placebo with identical me 		youth anxiety disorders
Children 		Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-
COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0 		↑ PMC6425733
12 weeks
📊 SRT: sertraline alone) over 12 weeks in
vs Pill placebo with identical me 		youth anxiety disorders
Children 		Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-
COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0 		↑ PMC6425733
12 weeks
📊 Sertraline
vs Pill placebo with identical me 		youth anxiety disorders
Children 		Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety
CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t 		↑ PMC6425733
12 weeks
📊 SRT: sertraline alone) over 12 weeks in
vs Pill placebo with identical me 		youth anxiety disorders
Children 		Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety
CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t 		↑ PMC6425733
12 weeks
📊 Sertraline
vs Pill placebo with identical me 		youth anxiety disorders
Adolescents 		Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-repor
COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= 		↑ PMC6425733
12 weeks
📊 SRT: sertraline alone) over 12 weeks in
vs Pill placebo with identical me 		youth anxiety disorders
Adolescents 		Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-repor
COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= 		↑ PMC6425733
12 weeks
📊 CBT, sertraline, and combination treatme
vs Pill placebo and comparisons a 		youth anxiety disorders
Children 		Youth self-reports revealed minimal between-group differences across treatment conditions, with only
b= -4.68, t= -2.80 (only significant com 		— PMC6425733
12 weeks
📊 sertraline) over 12 weeks in youth ages
vs Pill placebo and comparisons a 		youth anxiety disorders
Children 		Youth self-reports revealed minimal between-group differences across treatment conditions, with only
b= -4.68, t= -2.80 (only significant com 		— PMC6425733
12 weeks
📊 CBT, sertraline, and combination treatme
vs Comparison among three active 		youth anxiety disorders
Adolescents 		By week 36, parent reports of many youth outcomes were comparable across the three active treatment — PMC6425733
36 weeks
📊 sertraline) — continued assessment at 36
vs Comparison among three active 		youth anxiety disorders
Adolescents 		By week 36, parent reports of many youth outcomes were comparable across the three active treatment — PMC6425733
36 weeks
📊 Sertraline
vs Pill placebo with identical me 		internalizing psychopathology
Children 		Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-
COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0 		↑ PMC6425733
12 weeks
📊 SRT: sertraline alone) over 12 weeks in
vs Pill placebo with identical me 		internalizing psychopathology
Children 		Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-
COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0 		↑ PMC6425733
12 weeks
Synopsis

Combination treatment with CBT and sertraline was superior to placebo for reducing parent-reported youth anxiety symptoms at 12 weeks, with effect sizes of b = -15.7 (MASC-P) and b = -9.8 (SCARED), and was more effective than either treatment alone in the acute phase. (PMC6425733) Sertraline monotherapy was also superior to placebo at week 12, but the effect sizes (b = -11.1 for MASC-P and b = -7.9 for SCARED) were smaller than those seen with combination treatment, suggesting an added benefit from combining CBT and sertraline. (PMC6425733) By week 36, parent-reported outcomes were comparable across CBT, sertraline, and combination treatment, indicating that the acute superiority of combination therapy may not persist long-term. (PMC6425733)

Ask a follow-up question